U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842966) titled 'Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia' on Feb. 17.
Brief Summary: A study of the efficacy, safety, and tolerability of the drug 4-MUST at various doses compared to placebo in patients with chronic cholecystitis and biliary dyskinesia
Study Start Date: Oct. 17, 2024
Study Type: INTERVENTIONAL
Condition:
Chronic Cholecystitis
Biliary Dyskinesia
Intervention:
DRUG: 4-MUST
128 mg of trimebutine 4-methylumbelliferyl sulfate tablet.
DRUG: Placebo
Placebo tablet.
Recruitment Status: RECRUITING
Sponsor: Valenta Pharm JSC
Published by HT Digital Content Services with ...